Intrahepatic Cholangiocarcinoma (MSK, Clin Cancer Res 2021)

Summary

Intrahepatic Cholangiocarcinoma (MSK, Clin Cancer Res 2021) is a study catalogued by cBioPortal DataHub under the cancer-type code ihch. EvidenceHelix groups it with liver, bile duct and gallbladder studies.

Study description

Targeted sequencing of IMPACT and CMO samples

Text as published in the source's study metadata.

Citation & PubMed

Jolissaint et al. Clin Cancer Res 2021

Linked PubMed records: PMID 33963001

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

ihch_mskcc_2020

Short name

IHCH (MSK [2020])

Source cancer-type code

ihch

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Jolissaint et al. Clin Cancer Res 2021

• PubMed record 33963001 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• Intrahepatic Cholangiocarcinoma (MSK, Hepatology 2021)

  Targeted sequencing of 412 intrahepatic cholangiocarcinoma tumor/normal sample pairs.

  Liver, bile duct and gallbladderMSK studiesSource code ihchPubMed 1

• Intrahepatic Cholangiocarcinoma (Mount Sinai 2015)

  Whole-exome sequencing of 8 tumor-normal paired iCCA samples by Liver Cancer Program at the Icahn School of Medicine at Mount Sinai, in collaboration with Barcelona-Clínic Liver Cancer Group.

  Liver, bile duct and gallbladderOther published and consortium studiesSource code ihchPubMed 1

• Intrahepatic Cholangiocarcinoma (Shanghai, Nat Commun 2014)

  Whole exome sequencing of 103 tumor/normal sample pairs in 103 intrahepatic cholangiocarcinoma patients.

  Liver, bile duct and gallbladderOther published and consortium studiesSource code ihchPubMed 1

• Cholangiocarcinoma (MSK, Clin Cancer Res 2018)

  Targeted sequencing (MSK-IMPACT) of 195 tumor samples (194 with matched normals) from 192 cholangiocarcinoma patients.

  Liver, bile duct and gallbladderMSK studiesSource code cholPubMed 1

• Gallbladder Cancer (MSK, 2022)

  Targeted sequencing of 244 Gallbladder cases via MSK-IMPACT where investigators calculated the Overall survival time for 100 metastatic gallbladder patients.

  Liver, bile duct and gallbladderMSK studiesSource code gbcPubMed 1

• Gallbladder Cancer (MSK, Cancer 2018)

  Targeted Sequencing of 103 samples with matched normals from 101 Gallbladder cancer patients.

  Liver, bile duct and gallbladderMSK studiesSource code gbcPubMed 1

• Hepatocellular Carcinoma (MSK, Clin Cancer Res 2018)

  MSK-IMPACT sequencing of 127 Hepatocellular Carcinoma tumor samples with matched normals.

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

• Hepatocellular Carcinoma (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 1,370 hepatobiliary cancer samples (with 1366 matched normals) via MSK-IMPACT. This data is available under the Creative Commons BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-…

  Liver, bile duct and gallbladderMSK studiesSource code hccPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.